Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

rograms, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, financing capability, the potential dilutive effects of any financing, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of Public Relations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604) 822-0302, E-mail: , Internet: www.chemokine.net; Equicom Group, Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax: (416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

CONTACT: Chemokine Therapeutics Corp., Mr. Don Evans, Director of PublicRelations, Phone: (604) 822-0305 or 1-888-822-0305, Fax: (604) 822-0302,E-mail: , Internet: www.chemokine.net; Equicom Group,Joanna Longo, Investor Relations, Phone: (416) 815-0700 ext. 233, Fax:(416) 815-0080, E-mail: devans@chemokine.net jlongo@equicomgroup.com

Ticker Symbol: (Toronto:CTI.),(NASDAQ-OTCBB:CHKT)

'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:12/1/2008)... ROCKVILLE, Md., Dec. 1 ...rts publication in The Lancet , one of the world,...ials of its novel circadian regulator, experimenta... by Rajaratnam et al(1) is entitled "Melatonin ago...after sleep-time shift: two randomised controlled ...
(Date:12/1/2008)... St. Jude study shows the Prox1 gene is a two-way...thelial cells to be reprogrammed so that they lose...lial cells , , MEMPHIS, Tenn., Dec. 1 /PRNe...dren,s Research Hospital have discovered that a ce...ge its identity that it requires the constant expr...
(Date:12/1/2008)... ATLANTA, Dec. 1 GeoVax...a-based biotechnology company developing,human va...eficiency Virus) and,other infectious agents, ann...,Vaccine Trials will take place in twelve sites a...onducted in collaboration with The National Instit...
(Date:11/28/2008)... INDIANAPOLIS, Nov. 28 ...n its supplemental New Drug Application (sNDA) fro... Cymbalta(R) (duloxetine HCl),for the management ...cation in,the first half of 2009, adding data fro...osteoarthritis pain of the knee. , The deci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 1UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 2UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 3UCLA Research Shows Dramatic Savings for Medicaid When Head Start Parents Learn to Care for Kids Illnesses 5760 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 1NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 2NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 3NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 4NUCRYST Pharmaceuticals announces 2007 third quarter results 5758 5Shape Shifting on Veterans Day 5756 1Shape Shifting on Veterans Day 5756 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 1More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 2More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 3More Employers to Offer Workers Financial Incentives for Healthy Behavior 5754 4
...LE, Calif., April 16, 2007 /PRNewswire-FirstCall/ ...anism of action of,its anti-cancer agent BZL101, w...r late stage breast cancer at the American,Associa...os Angeles,Convention Center in Los Angeles, CA, A...n will describe the pathway for,cancer cell apopto...
...agonist Demonstrates Clinical Activity, a Novel Me...other HCV Inhibitors-, NEW HAVEN, Conn., April 16,...uticals, Inc. today announced the presentation of,... one of,Achillion,s NS4A antagonists, ACH-806, for...n at the 42nd Annual Meeting of the,European Assoc...
Other Medicine Technology:Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 2Bionovo to Present Recent Findings of BZL101, Its Anti-cancer,Agent, at the American Association of Cancer Research 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 2Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 3Achillion Presents Positive Data on Novel Mechanism for Treating,HCV at EASL Annual Meeting 4
(Date:12/2/2008)...rathon Health, a leading provider of onsite health...that New Balance, the athletic products company, h...and manage onsite health clinics and to provide he... in Maine , Burlington, V...eading provider of onsite employee health services...
(Date:12/2/2008)...r many families, the problem with the holidays is ...sight into how caregivers of aging parents can bri... experience. , San Mateo,...the stress of the holiday season is family, especi...expert Esther Koch , founder of Encore Managemen...
(Date:12/2/2008)...tional Non-profit Launches Age-related Macular Deg...Cost to Eligible Patients and Free Eye-Healthy Coo...A (Vocus) December 2, 2008 -- "Do You See Wha...disease known as Age-related Macular Degeneration ..., ,Picture this…. a large black hole in the...
(Date:12/2/2008)...ion Health announces that the SouthEast Alaska Reg..., has selected the Rhapsody™ Integration Eng..., radiology, pharmacy, laboratory and business pro...o extend connectivity to statewide systems such as...y) and AKAIMS (an MIS and clinical documentation t...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3
...ne of the top organ transplant hospitals in Califo...egations a Saudi national improperly received an o...nts.// The Los Angeles Times reported that offici... discovered that, following the transplant, some h...
...w new hope on the horizon for trigeminal neuralgia...fe Stereotactic Radiosurgery (GKRS) is an effectiv...n.// Researchers at the Comprehensive Cancer Cent...Medical found that the GKRS technique relived pain...
...nal survey conducted by Synovate India and sponsor... though Indians use high quality toothbrush and th... level of oral hygiene awareness was surprisingly ... admitted that they have never been to a dentist i...
...In what is the first promising news regarding the ...rvices department (ANTSZ) has said that a prototyp... proving effective against birds. 'The effectiven...he Asian H5N1 strain of bird flu is proved among p...
Other Medicine News:
...ing test for determining the presence of clinical ...randed system is considered the manual standard, a...r system meets defined NCCLS/ICSH guidelines desig...alized systems are also available for pediatric ap...
DAVINCI® performs all required steps primary tube sampling, reagent dispensing, microplate incubation, washing and optical reading.
...acids and is variably N-glycosylated. The variatio...tes of between 43 and 56 kDa. Insulin-like growth ... high affinity but do not bind insulin. Of the six...terized at this time, IGFBP-3 has been shown to be...
For the detection and semi-quantitation of antibodies against the Scl-70 antigen in serum as an aid in the diagnosis of autoimmune disease. The test can be performed either manually or in conjunction
Medicine Products: